Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend

An update from Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) is now available.

On March 13, 2026, Ascentage Pharma Group International announced that its board of directors will convene a meeting on March 25, 2026 to review and, if appropriate, approve the group’s audited annual results for the year ended December 31, 2025. The board will also consider whether to declare a final dividend, signaling a key decision point for shareholder returns and offering investors clarity on the company’s financial performance and capital allocation stance for the past fiscal year.

The most recent analyst rating on (AAPG) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.

Spark’s Take on AAPG Stock

According to Spark, TipRanks’ AI Analyst, AAPG is a Neutral.

The score is primarily held back by weak financial quality (ongoing losses, negative cash flow, and high leverage risk) and bearish technical conditions (negative MACD and price below key moving averages). Rapid revenue growth provides some offset, but valuation signals are limited due to negative earnings and no dividend data.

To see Spark’s full report on AAPG stock, click here.

More about Ascentage Pharma Group International Unsponsored ADR

Ascentage Pharma Group International is a biopharmaceutical company headquartered in Suzhou, China, with its holding entity incorporated in the Cayman Islands. Listed in Hong Kong under stock code 6855, the group focuses on pharmaceutical research and development and operates through a board structure that includes executive, non-executive and independent non-executive directors with international governance experience.

Average Trading Volume: 3,092

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.15B

Learn more about AAPG stock on TipRanks’ Stock Analysis page.